

Review

Virtual Screening of Protein Data Bank via Docking Simulation Identified the Role of Integrins in Growth Factor Signaling, the Allosteric Activation of Integrins, and P-Selectin as a New Integrin Ligand

Yoshikazu Takada ^{1,2,*} , Masaaki Fujita ¹ and Yoko K. Takada ¹

¹ Department of Dermatology, UC Davis School of Medicine, Sacramento, CA 95817, USA; fujita.masaaki@e3.kepco.co.jp (M.F.); yoktakada@ucdavis.edu (Y.K.T.)

² Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

* Correspondence: ytakada@ucdavis.edu

Abstract: Integrins were originally identified as receptors for extracellular matrix (ECM) and cell-surface molecules (e.g., VCAM-1 and ICAM-1). Later, we discovered that many soluble growth factors/cytokines bind to integrins and play a critical role in growth factor/cytokine signaling (growth factor–integrin crosstalk). We performed a virtual screening of protein data bank (PDB) using docking simulations with the integrin headpiece as a target. We showed that several growth factors (e.g., FGF1 and IGF1) induce a integrin-growth factor-cognate receptor ternary complex on the surface. Growth factor/cytokine mutants defective in integrin binding were defective in signaling functions and act as antagonists of growth factor signaling. Unexpectedly, several growth factor/cytokines activated integrins by binding to the allosteric site (site 2) in the integrin headpiece, which is distinct from the classical ligand (RGD)-binding site (site 1). Since 25-hydroxycholesterol, a major inflammatory mediator, binds to site 2, activates integrins, and induces inflammatory signaling (e.g., IL-6 and TNF α secretion), it has been proposed that site 2 is involved in inflammatory signaling. We showed that several inflammatory factors (CX3CL1, CXCL12, CCL5, sPLA2-IIA, and P-selectin) bind to site 2 and activate integrins. We propose that site 2 is involved in the pro-inflammatory action of these proteins and a potential therapeutic target. It has been well-established that platelet integrin α IIb β 3 is activated by signals from the inside of platelets induced by platelet agonists (inside-out signaling). In addition to the canonical inside-out signaling, we showed that α IIb β 3 can be allosterically activated by inflammatory cytokines/chemokines that are stored in platelet granules (e.g., CCL5, CXCL12) in the absence of inside-out signaling (e.g., soluble integrins in cell-free conditions). Thus, the allosteric activation may be involved in α IIb β 3 activation, platelet aggregation, and thrombosis. Inhibitory chemokine PF4 (CXCL4) binds to site 2 but did not activate integrins. Unexpectedly, we found that PF4/anti-PF4 complex was able to activate integrins, indicating that the anti-PF4 antibody changed the phenotype of PF4 from inhibitory to inflammatory. Since autoantibodies to PF4 are detected in vaccine-induced thrombocytopenic thrombosis (VIPP) and autoimmune diseases (e.g., SLE, and rheumatoid arthritis), we propose that this phenomenon is related to the pathogenesis of these diseases. P-selectin is known to bind exclusively to glycans (e.g., sLex) and involved in cell–cell interaction by binding to PSGL-1 (CD62P glycoprotein ligand-1). Unexpectedly, through docking simulation, we discovered that the P-selectin C-type lectin domain functions as an integrin ligand. It is interesting that no one has studied whether P-selectin binds to integrins in the last few decades. The integrin-binding site and glycan-binding site were close but distinct. Also, P-selectin lectin domain bound to site 2 and allosterically activated integrins.

Keywords: integrins; receptors; growth factor signaling



Citation: Takada, Y.; Fujita, M.; Takada, Y.K. Virtual Screening of Protein Data Bank via Docking Simulation Identified the Role of Integrins in Growth Factor Signaling, the Allosteric Activation of Integrins, and P-Selectin as a New Integrin Ligand. *Cells* **2023**, *12*, 2265. <https://doi.org/10.3390/cells12182265>

Academic Editor: Wayne Carver

Received: 14 August 2023

Revised: 2 September 2023

Accepted: 7 September 2023

Published: 13 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Several Growth Factors Bind to the Classical Ligand-Binding Site (Site 1) of Integrins

Integrins are superfamily of cell surface heterodimers that recognize extracellular matrix (ECM), cell surface ligands (e.g., VCAM-1 and ICAM-1), and growth factors/cytokines. Integrins play important roles in normal biological processes (e.g., wound-healing and hemostasis) and in the pathogenesis of diseases [1,2]. Integrin–ligand interactions are thus a major therapeutic target. Through the virtual screening of a protein data bank (PDB) using docking simulation, we found that several growth factors (e.g., FGF1, FGF2, IGF1, IGF2, and neuregulin-1) [3–7] were bound to the classical ligand-binding site (site 1) of integrins, which was defined by the crystal structure of the RGD- $\alpha\beta 3$ complex [8,9]. These growth factors induced an integrin growth factor-cognate receptor ternary complex on the surface (ternary complex model) (Figure 1). Notably, the FGF1 mutant defective in integrin binding (Arg50 to Glu, R50E) was defective in signaling and ternary complex formation and suppressed tumor growth and angiogenesis (dominant-negative antagonists), although they still bind to FGF receptor [10,11]. We obtained similar results in FGF2, IGF1, IGF2, and neuregulin-1. We propose that the strategy we used is a useful platform for drug discovery.




Figure 1. Integrin–IGF1–IGF1R ternary complex model. Type 1 insulin-like growth factor receptor (IGF1R) is a receptor tyrosine kinase that regulates cell growth and proliferation and can be activated by IGF1, IGF2, and insulin. IGF1R is proteolytically cleaved into the extracellular α chain and intracellular β chain (disulfide-linked). Two α and two β chains make up the IGF1R ($\alpha 2\beta 2$). IGF1 binds to integrins $\alpha v\beta 3$ and $\alpha 6\beta 4$. This wild type IGF1 induces the integrin–IGF1–IGF1R ternary complex on the cell surface. This process is required for IGF1 signaling. The IGF1 mutant (R36E/R37E) is defective in integrin binding and ternary complex formation, although it still binds to IGF1R. R36E/R37E is defective in signaling and acts as a dominant-negative antagonist of IGF1 signaling and suppress tumor growth [10]. This indicates that IGF1 binding to IGF1R may not be sufficient for IGF1 signaling. This model can be applied to other growth factors, such as FGF1 [11], FGF2 [5], IGF2 [12], neuregulin-1 [7], and CX3CL1 [13].

The advantages of docking simulation is that we did not need any pre-knowledge or bias about potential integrin binding, and new integrin binding proteins are identified only based on docking energy. In most cases, we were able to prove that newly identified

integrin ligands really bind to integrins as predicted by the simulation, and mutagenesis studies prove that the docking poses are correct. Most importantly, the newly found ligand binding to integrins have been shown to have important biological roles, as we describe in this review. The disadvantage of our strategy is that models of new ligands binding to integrins are so unexpected and often are not consistent with currently popular models (e.g., growth factor signaling and P-selectin). We are confident that the new integrin–ligand interaction model will eventually be generally accepted. Currently, we are trying to further develop potential therapeutics based on the antagonists we discovered, in addition to documenting as many new integrin ligands as possible.

2. Are Integrins Still Practical Targets for Anti-Cancer Therapy?

It has been shown that clinical trials with anti-integrin inhibitors have globally failed to demonstrate therapeutic benefits, and no inhibitors have been registered as anti-cancer drugs [14]. Our models of growth factor–integrin crosstalk suggest that growth factors binding to integrins and the resulting integrin–growth factor cognate receptor complex is required for growth factor signaling. If growth factors bind to multiple integrins, blocking one or two integrins may not be sufficient to block signaling. The blocking of one or two integrins may be compensated by others that bind to the same growth factors. We have shown that growth factor mutants defective in integrin binding (e.g., FGF1 R50E and IGF1 R36E/K37E) [10,11] result in the suppression of signaling and the mutants act as dominant-negative antagonists although the mutants still bind to cognate receptors (e.g., FGFR and IGF1R). Such mutations are expected to simultaneously block binding to multiple integrins. We propose that such dominant-negative mutants should be considered as potential therapeutics.

3. Several Chemokines Are Integrin Ligands

Unlike most chemokines, CX3CL1 is not synthesized by leukocytes but is expressed on the cell surface of IL-1- and TNF α -activated endothelium as a membrane-bound form [15]. Soluble CX3CL1 is released using metalloproteinases ADAM10 and ADAM17 [16–18]. CX3CL1's highly selective receptor CX3CR1 (GPCR) is expressed in monocytes, T cells, NK cells, and neurons [19–21]. Interactions between membrane-bound CX3CL1 and CX3CR1 promote leukocyte adhesion to the endothelium [19,22,23]. We identified the chemokine domain of CX3CL1 (Fractalkine) [13] as a new ligand for integrins $\alpha v\beta 3$, $\alpha 4\beta 1$, and $\alpha 5\beta 1$ and that CX3CL1 and integrins bind to CX3CR1 simultaneously [13] (Figure 2). The CX3CL1 mutant defective in integrin binding (K36E/R37E) was generated by introducing mutations in the predicted integrin-binding interface. This mutant was defective in signaling and suppressed CX3CL1 signaling as an antagonist, although it still bound to CX3CR1 [13], indicating that the direct integrin binding to CX3CL1 and subsequent integrin–CX3CL1–CXCR4 ternary complex formation is required for its signaling functions. The K36E/R37E mutant suppressed leukocyte recruitment in the peritonitis model, indicating that this mutant has therapeutic potential [13].




Figure 2. Docking simulation of CX3CL1 chemokine domain (FKN-CD) binding to $\alpha v \beta 3$ with an inactive conformation predicting a new ligand-binding site (site 2). (a) A docking model of a FK-N-CD–integrin $\alpha v \beta 3$ (active) interaction [24]. The headpiece of ligand-bound form of integrin $\alpha v \beta 3$ (PDB code 1L5G) was used as a target. The model predicts that FK-N-CD (PDB code 1F2L, red) binds to the classical RGD-binding site of the integrin $\alpha v \beta 3$ headpiece (site 1). (b) A docking model of FK-N-CD–integrin $\alpha v \beta 3$ (inactive) interaction. The headpiece of an inactive form of integrin $\alpha v \beta 3$ (PDB code 1JV2) was used as a target. The model predicts the position of the second FK-N-CD-binding site (site 2). (c) Superposition of two models shows that the positions of two predicted FK-N-CD binding sites are distinct. (d) Position of the $\beta 3$ peptide (267–287, blue) at site 2 (S2- $\beta 3$). Most of amino acid residues in this peptide are predicted to interact with FK-N-CD.

4. Several Growth Factors Bind to the Allosteric Site (Site 2) and Allosterically Activate Integrins

We unexpectedly discovered that CX3CL1 (fractalkine, FKN) activated soluble integrin $\alpha v \beta 3$ in 1 mM Ca^{2+} in cell-free conditions [25] (Figure 2), indicating that this activation does not require inside-out signaling. Docking simulation between CX3CL1 chemokine domain (FKN-CD in Figure 2) and closed headpiece/inactive integrin $\alpha v \beta 3$ (1JV2.pdb) predicted that CX3CL1 binds to a binding site that is distinct from the classical binding site (site 1). We realized that this new binding site should be an allosteric site (site 2) in an analogy to allosteric enzymes. So, we hypothesized that CX3CL1 can allosterically activate integrins. We discovered that CX3CL1 activated soluble integrin $\alpha v \beta 3$ in 1 mM Ca^{2+} (to

keep $\alpha v\beta 3$ in an inactive state) in cell-free conditions in ELISA-type activation assays, as predicted from the docking simulation.

To study whether CX3CL1 activates $\alpha v\beta 3$, the wells of 96-well microtiter plate were coated with a fibrinogen fragment ($\gamma C399tr$), a specific ligand for $\alpha v\beta 3$, and were blocked with BSA. Then, soluble $\alpha v\beta 3$ ectodomain was incubated with immobilized $\gamma C399tr$ in the presence or absence of CX3CL1 at room temperature in 1 mM Ca^{2+} . In the absence of CX3CL1, $\alpha v\beta 3$ does not bind to $\gamma C399tr$. We found that soluble $\alpha v\beta 3$ bound to $\gamma C399tr$ in the presence of CX3CL1, indicating that CX3CL1 activated soluble $\alpha v\beta 3$ in 1 mM Ca^{2+} in cell-free conditions.

This activation seems to require the direct binding of CX3CL1 to $\alpha v\beta 3$, since the CX3CL1 mutant defective in integrin binding did not activate $\alpha v\beta 3$. We assumed that this activation of soluble integrin should be allosteric and the second binding site should regulate the classical binding site, since otherwise CX3CL1 and the fibrinogen fragment, a specific ligand to $\alpha v\beta 3$, will compete for binding to $\alpha v\beta 3$, instead of facilitating binding. We identified the second ligand-binding site (site 2), which is distinct from the classical ligand-binding site (site 1) in the integrin headpiece via docking simulation using inactive/close headed integrin $\alpha v\beta 3$ as a target. We showed that peptides from site 2 of the integrin β subunit bound to CX3CL1 and blocked integrin activation by CX3CL1 [25]. Therefore, we concluded that site 2 is the allosteric binding site and is involved in allosteric activation of integrins.

We showed that other integrin ligands secreted phospholipase A2 type IIA (sPLA2-IIA) [26], CXCL12 [27], and CD40L [28] activated integrins by binding to site 2, indicating that this mechanism of integrin activation is not limited to CX3CL1. sPLA2-IIA was previously shown to bind to site 1 [29].

It has been reported that 25-hydroxycholesterol, a lipid pro-inflammatory mediator, activates integrins by binding to site 2 of integrins and induced pro-inflammatory signals (e.g., NF- κB activation) [30]. It is likely that the ligand binding to site 2 induces pro-inflammatory signals.

5. Several Inflammatory Cytokines (CXCL12, CCL5, sPLA2-IIA, CD40L) Bind to and Activate Integrin $\alpha IIb\beta 3$

Integrin $\alpha IIb\beta 3$ is a receptor for several proteins, including fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin, vitronectin, and the von Willebrand factor (VWF). The activation of $\alpha IIb\beta 3$ is a key event that triggers platelet aggregation by inducing $\alpha IIb\beta 3$ binding to fibrinogen, leading to bridge formation between platelets [31,32]. It has been proposed that the activation of integrin $\alpha IIb\beta 3$ is induced exclusively by the inside-out signaling of platelet agonists (e.g., thrombin, ADP, collagen), which bind to receptors on the cell surface. Signals received by other receptors induce the binding of talin and kindlin to the cytoplasmic end of the integrin β subunit at sites of actin polymerization [31–33]. It has, however, been proposed that canonical integrin activation pathways via platelet agonists induce integrin binding to multivalent ligands (e.g., ligand-mimetic antibody, Pac-1 IgM specific for $\alpha IIb\beta 3$, with potential 10-binding sites) but do not enhance ligand binding affinity to monovalent ligands [34,35]. Since the activation of integrins through the binding of chemokines to site 2 (allosteric activation) enhanced the binding of monovalent ligands to integrins, we propose that site 2-mediated allosteric integrin activation is distinct from the integrin activation via the canonical inside-out signaling pathway.

6. Allosteric Activation by Chemokine Binding to Site 2

We wondered whether these chemokines bind to $\alpha IIb\beta 3$ and activate this integrin in an allosteric manner. What is the contribution of inside-out signaling and allosteric activation? CXCL12 and CCL5 are stored in platelet granules and rapidly transported to the surface upon platelet activation [36], and CX3CL1 is expressed on activated endothelial cells. These chemokines are overproduced during inflammation (e.g., cytokine storm). It is unclear whether these chemokines play a role in the activation of $\alpha IIb\beta 3$ on platelet activation or

during inflammation. Here, we demonstrate that these chemokines are new ligands for α IIb β 3 and activated soluble and cell-surface α IIb β 3 by binding to site 2. The activation of α IIb β 3 by the chemokines was suppressed by peptides from site 2, indicating that their binding to site 2 is critical. They activated cell surface α IIb β 3 on CHO cells more quickly (half-maximal response within 1 min) and at much lower concentrations (1–10 ng/mL) of chemokines than in soluble α IIb β 3, probably because chemokines are concentrated by binding to cell surface proteoglycans. CHO cells do not have the machinery for inside-out signaling or cognate receptors for these chemokines, indicating that inside-out signaling or receptors for these chemokines are not involved. Notably, the activation of α IIb β 3 by the chemokines was much stronger than that of 1 mM Mn^{2+} . These findings suggest that platelet integrin α IIb β 3 can be rapidly activated by pro-inflammatory chemokines independent of inside-out signaling. α IIb β 3 activation by pro-inflammatory chemokines is biologically relevant and possibly constitutes a missing link between inflammation and thrombosis.

The mechanism of integrin activation has been extensively studied in integrin α IIb β 3 as a model. α IIb β 3 is present as an inactive form and rapidly activated upon platelet activation. The activation of α IIb β 3 is a key event that triggers platelet aggregation by inducing α IIb β 3 binding to fibrinogen, leading to bridge formation between platelets [31,32]. It has been proposed that the activation of integrin α IIb β 3 is induced exclusively by inside-out signaling by platelet agonists (e.g., thrombin, ADP, collagen), which bind to receptors on the cell surface. Signals received by other receptors (e.g., the Thrombin receptor) induce the binding of talin and kindlin to the cytoplasmic end of the integrin β subunit at the sites of actin polymerization [31–33]. It has, however, been proposed that canonical integrin activation pathways by platelet agonists induce integrin binding to multivalent ligands (e.g., the ligand-mimetic antibody, Pac-1 IgM specific for α IIb β 3, with 10 potential binding sites) but do not enhance ligand-binding affinity to monovalent ligands [34,35].

Thus, we studied whether the platelet integrin α IIb β 3 can be activated by these chemokines in an allosteric manner upon platelet activation. Integrin α IIb β 3 is a receptor for several proteins, including fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin, vitronectin, and the von Willebrand factor (VWF). Since the activation of integrins via the binding of chemokines to site 2 (allosteric activation) enhanced the binding of monovalent ligands to integrins, we propose that site 2-mediated allosteric integrin activation is distinct from the integrin activation by the canonical inside-out signaling pathway.

7. Allosteric Activation of α IIb β 3 by Pro-Inflammatory Proteins

Importantly, many pro-inflammatory proteins (e.g., P-selectin, CCL5, CXCL12, CD40L) are stored in platelet granules (not CX3CL1) and rapidly transported to the surface. We thus hypothesized that α IIb β 3 on platelets can be allosterically activated by pro-inflammatory proteins stored in platelet granules upon platelet activation by binding to site 2. We discovered that these proteins bind to and allosterically activate integrins, including α IIb β 3 (see below). Chemokines are over-expressed during inflammation (e.g., cytokine storm and autoimmune diseases) and chemokines from outside of platelets may also allosterically activate α IIb β 3. Also, the transmembrane chemokine CX3CL1 is expressed on the surface of endothelial cells activated by pro-inflammatory cytokines [15] but not in the platelet granules. We hypothesize that CX3CL1 allosterically activates platelet α IIb β 3 and facilitates platelet adhesion to the vascular wall during inflammation. CXCL12 (SDF-1) is ubiquitously expressed in many tissues and cell types. CXCL12 is a potent chemoattractant for leukocytes and is believed to regulate signaling events through two different GPCRs, CXCR4 and CXCR7, in leukocytes [37–40]. The binding of CXCL12 to CXCR4 induces trimeric G protein signaling [41,42]. CXCL12 activated integrins α v β 3, α 4 β 1, and α 5 β 1 by binding to site 2 [27], indicating that this mechanism of integrin activation is not limited to CX3CL1. CCL5 (Rantes) is a pro-inflammatory chemokine, recruiting leukocytes to the site of inflammation.

8. CD40L Is an Integrin Ligand

CD40L is a key immunomodulatory factor and a major therapeutic target. CD40 is a cell surface receptor that belongs to the tumor necrosis factor-R (TNF-R) family and was first identified and functionally characterized on B lymphocytes [43]. Its critical role in T cell-dependent humoral immune responses was demonstrated by patients with the hyper-IgM syndrome type 1 (HIGM1), in which switching IgM to IgG is defective due to mutations in CD40L.

CD40L is a type II protein ligand member of the tumor necrosis factor (TNF) superfamily that, via interaction with CD40, is a key immunomodulatory factor responsible for modulating nearly all aspects of the adaptive immune response. CD40L is expressed as a transmembrane form and released as a soluble form (sCD40L) through proteolytic cleavage. The CD40L/CD40 interaction is required for enhancing antigen presenting the functions of dendritic cells, macrophages, and B cells; the maturation of humoral responses; and the enhancement of effector T cell responses [44]. CD40L is a key player in chronic autoimmune inflammatory diseases, including systemic lupus erythematosus (SLE), diabetes, multiple sclerosis (MS), and chronic kidney disease [24,45]. Clinical trials using humanized or chimeric anti-CD40L monoclonal antibodies blocking CD40L/CD40 interactions were undertaken in the early 2000s. Unfortunately, progress was halted due to the incidence of thromboembolic events in clinical trials. It is thus necessary to seek alternative ways to block CD40/CD40L signaling.

It has been believed that trimeric CD40L is biologically active but monomeric CD40L is not. CD40L levels markedly increase in certain pathologic conditions (SLE and RA), but CD40L exists mainly in a monomeric form [46]. CD40L simultaneously binds to integrin $\alpha 5\beta 1$ and CD40, but it is unclear whether integrins and CD40 work together. The contribution of integrins to CD40/CD40L signaling has been largely ignored [47,48], and there is a huge gap of knowledge in this area. It has been reported that CD40L stabilizes arterial thrombi through binding to integrin $\alpha IIb\beta 3$ [49]. $\alpha IIb\beta 3$ recognizes the KGD motif at the N-terminus of CD40L (residues 115–117 of CD40L).

9. The Integrin-Binding Site of CD40L Is in the Trimeric Interface [6]

We examined whether CD40L binds to integrin $\alpha v\beta 3$ using a docking simulation between monomeric CD40L (PDB code 1ALY) and the headpiece of $\alpha v\beta 3$ (PDB code 1L5G). The docking simulation predicts that monomeric CD40L will bind to the classical RGD-binding site of $\alpha v\beta 3$ (site 1) (Figure 3). Notably, the integrin-binding site in CD40L is predicted to be in the trimeric interface.

Mutating amino acid residues at the predicted integrin-binding sites in CD40L reduces integrin binding. We found that mutating the amino acid residues in the predicted integrin-binding interface in the trimeric interface (Y170E, H224E/G226E, and G252E mutations) significantly reduced integrin binding. These findings suggest that the critical amino acid residues for integrin binding are in the trimeric interface of CD40L. These results are consistent with the docking model, indicate that integrins bind to monomeric sCD40L through binding sites that are cryptic in CD40L trimers.




Figure 3. (A) The clustering of HIGM1 mutants at the site 1 and site 2 binding sites in CD40L. A previous study showed that eight HIGM1 mutants are clustered in the trimeric interface of CD40L (A–C) [6]. The four HIGM1 mutants are clustered at the site 2 binding site of CD40L on the outside of the CD40L trimer. In contrast to $\alpha v\beta 3$, $\alpha IIb\beta 3$ binding sites in CD40L are outside of the CD40L trimer [50].

10. The sCD40L Mutants Defective in Integrin Binding Still Bind to CD40

It is possible that the Y170E, H224E/G226E, and G252E mutations did not bind to integrin $\alpha 5\beta 1$ because they were structurally not intact. We found, however, based on ELISA-type binding assays, that the sCD40L mutants defective in integrin binding still could bind to CD40. This indicates that they were properly folded and that the integrin-binding and CD40-binding sites are distinct.

The sCD40L mutants defective in integrin-binding are defective in inducing NF- κ B activation. We found that wild type sCD40L induced robust NF- κ B activation but sCD40L mutants defective in integrin binding did not induce NF- κ B activation at all. These findings indicate that the sCD40L mutants defective in integrin binding are defective in signaling although they still bind to CD40, and that the binding of sCD40L to CD40 is not sufficient for signaling functions.

The sCD40L mutants defective in integrin binding are defective in inducing B cell activation. We studied the effect of sCD40L mutations on B cell activation. Enriched human B cells were cultured with or without soluble CD40L (wild type or 3 mutants), and their phenotype was analyzed using flow cytometry. We used the expression levels of CD80 as markers of B cell activation. Wild type sCD40L increased CD80 expression, whereas the rest of mutants did not. These findings indicate that the sCD40L mutants defective in integrin binding are defective in inducing B cell activation. It is thus highly likely that the binding of monomeric CD40L to integrins through the integrin-binding site in the trimeric interface is critically involved in CD40/CD40L activation via ternary complex formation.

11. Several HIGM1 Mutants Are Defective in Integrin Binding

Somatic mutations in CD40L result in HIGM1 [51]. The CD40L missense mutations induce defects in the structure and trimerization of CD40L, since the mutations are mostly located in the trimeric interface. Interestingly, we noticed that several HIGM1 mutations

are clustered in the integrin-binding site in the trimeric interface of CD40L (Y170C, Q174R, T176I, A208D, H224Y, G226A, G227V). These HIGM1 mutants are not exposed to the surface in CD40L trimer. Six out of eight mutants were defective in integrin binding. Notably, these mutations had little or no effect on the binding of CD40. The HIGM1 mutants defective in integrin binding were defective in NF- κ B activation using CD40L reporter cells. These findings indicate that several genetic mutations in the integrin-binding site within the trimeric interface reduced integrin binding and thereby induced CD40L functional defects, leading to HIGM1. These findings are consistent with the idea that direct integrin binding to monomeric CD40L plays a role in CD40/CD40L signaling. Therefore, we propose that the defective integrin binding may be a possible cause of defective CD40L functions in HIGM1. Integrin α v β 3 binds to CD40L in a KGD (residues 115–117 of CD40L)-independent manner.

Consistently, our docking simulation predicted that CD40L binds to α v β 3 with high affinity. We thus examined whether soluble integrin α v β 3 when fully activated by 1 mM Mn^{2+} binds to immobilized sCD40L using ELISA-type binding assays. We found that α v β 3 bound to the wild type sCD40L in a dose-dependent manner. These findings suggest that integrin α v β 3 binds to CD40L in the KGD-independent manner (since the soluble CD40L that we used does not have the KGD motif (residues 115–117) at the N-terminus). Mn^{2+} strongly supported the binding of soluble α v β 3 to immobilized sCD40L but Mg^{2+} and Ca^{2+} did not, indicating that α v β 3 should be fully activated. This is consistent with the idea that α v β 3 binds to CD40L. We found that the HIGM1 mutations (Y170C, Q174R, T176I, G227V, and L258S) reduced the binding of soluble α v β 3.

Also, several CD40L mutants defective in integrin binding and most HIGM1 mutants (which are also defective in integrin binding) were antagonists of CD40L/CD40 signaling. Thus, they have therapeutic potential.

12. CD40L Allosterically Activates Integrins by Binding to Site 2

Docking simulation predicted that CD40L binds to the allosteric site (site 2) as well as the classical ligand-binding site (site 1) of integrin α v β 3 [28]. We thus hypothesized that CD40L can allosterically activate integrins by binding to site 2. We found that CD40L bound to site 1 of soluble integrins α v β 3, α 4 β 1, and α 5 β 1 and activated them in an allosteric manner by binding to site 2 [28] (Figure 3). The binding interface of CD40L to these integrins is located on the outer surface of CD40L trimer, and another group of functionally defective HIGM1 mutants (S128R/E129G, L155P, K143T, and G144E mutants) were clustered in this region. We thus propose that CD40L binding to integrin site 1 and to CD40 and the subsequent integrin/CD40L/CD40 ternary complex formation is involved in CD40L/CD40 signaling and that integrin should be activated through the binding of CD40L to site 2 in advance.

13. CD40L Binds to Site 1 and Allosterically Activates Platelet Integrin α IIB β 3 by Binding to Site 2

CD40L is stored in platelet granules and rapidly transferred to the surface upon platelet activation by platelet agonists (e.g., thrombin and ADP). CD40L in activated platelets has been shown to play a role in atherosclerosis formation and stabilize the thrombus [52,53]. α IIB β 3 is known to recognize the KGD motif of CD40L (residues 115–117 of CD40L). α 5 β 1 does not require the KGD motif [54]. However, the specifics of CD40L binding to α IIB β 3 are unclear. We showed that CD40L binds to α IIB β 3 in a KGD-independent manner using CD40L, which lacks the KGD motif. Two HIGM1 mutants, S128E/E129G and L155, reduced the binding of CD40L to the classical ligand-binding site (site 1) of α IIB β 3, indicating that α IIB β 3 binds to the outer surface of the CD40L trimer. Also, CD40L bound to site 2 of α IIB β 3 and allosterically activated α IIB β 3 without inside-out signaling. Two HIGM1 mutants, K143T and G144E, on the surface of trimeric CD40L suppressed CD40L-induced α IIB β 3 activation [50]. These findings suggest that CD40L binds to α IIB β 3 in a manner different from that of α v β 3 and α 5 β 1 and induces α IIB β 3 activation. HIGM1 mutations

are clustered in α IIb β 3 binding sites in CD40L and are predicted to suppress thrombus formation and immune responses through α IIb β 3.

14. P-Selectin (CD62P) C-Type Lectin Domain Functions as an Integrin Ligand

CD62P is a member of the selectin family and functions as a Ca^{2+} -dependent receptor, which binds to the sialylated fucosylated sugars decorating receptors on neutrophils, monocytes, and platelets. CD62P is stored in the α -granules of platelets and Weibel–Palade bodies of endothelial cells [55] and is transferred to the plasma membrane upon activation [56,57]. The extracellular region of CD62P is composed of three different domains like other selectin types: a C-type lectin-like domain in the N-terminus, an EGF-like domain, and complement-binding protein-like domains with short consensus repeats (~60 amino acids). CD62P is anchored in the transmembrane region followed by a short cytoplasmic tail region [58]. CD62P mediates the rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation through interaction with CD62P glycoprotein ligand-1 (PSGL-1) [59]. Thus, it is a major therapeutic target for cardiovascular diseases, inflammation, and cancer metastasis [60]. Its recognition of the sialyl Lewis X via the lectin domain has exclusively been targeted for drug development, which highlights the opportunity to discover new drug targets to alternate ligands.

The virtual screening of the protein data bank provided the basis of our CD62P- α v β 3 docking model, which predicts that the ligand-binding site of integrins resides within site 1 and is distinct from the glycan-binding site of CD62P [61] (Figure 4). We identified amino acid residues critical for integrin binding in the lectin domain by introducing mutations in the predicted integrin-binding site (e.g., the K16E/R17E mutation). The E88D mutation that is known to block glycan binding [62] minimally affected integrin binding. These findings suggest that CD62P acts as an integrin ligand on activated endothelial cells, leukocytes, and platelets. Further, it is possible that CD62P mediates cell–cell interactions by binding to integrins (Figure 5) simultaneously to its capacity to mediate glycan binding and rolling. In addition, the lectin domain of CD62P binding to site 2 can activate integrin and thus mediate outside-in signaling during platelet and leukocyte recruitment [61].




Figure 4. The CD62P lectin domain binding to integrin and PSGL-1. (a) The CD62P- α v β 3 docking model was superposed with the crystal structure of the CD62P-PSGL1 peptide complex (1G1S.pdb). The superposed model predicts that the integrin-binding site and PSGL-1-binding site are distinct. R16/K17 of the CD62P lectin domain is close to integrin α v β 3, and E88 of the lectin domain is close to PSGL-1 peptide and glycan. (b) Docking simulation of the interaction between open/active α v β 3(1L5G.pdb) and the CD62P lectin domain (1G1Q.pdb) was performed using Autodock3. The specificity loop (residues 177–184 of β 3) is next to site 1. This loop is located between site 1 and site 2.




Figure 5. Potential role of CD62P binding to integrins. CD62P is stored in endothelial cells and platelet granules and transported to the surface upon endothelial or platelet activation. It has been proposed that CD62P plays a role in cell–cell interactions during leukocyte extravasation or cancer metastasis by binding to P-selectin glycan ligand-1 (PSGL-1) but the expression of PSGL-1 is limited to leukocytes. P-selectin–integrin interaction is expected to play a role in cell–cell interactions and signaling, since integrins are widely expressed.

15. PF4 Is an Inhibitory Chemokine: Anti-PF4 Changes the Phenotype of Inhibitory Chemokine PF4 to Pro-Inflammatory Chemokine

As the novel SARS-CoV-2 virus continues to infect numerous individuals worldwide, one of the leading approaches in dealing with the global health crisis is vaccination against COVID-19. It has recently been reported that vaccination may result in a vaccine-induced catastrophic thrombotic thrombocytopenia (VITT) disorder. This disorder presents as extensive thrombosis in atypical sites, primarily in the cerebral venous, alongside thrombocytopenia and the production of autoantibody against platelet-factor 4 (PF4, chemokine CXCL4). This rare adverse effect extremely resembles the clinical presentation of the classical immune-mediated heparin-induced thrombocytopenia (HIT) disorder, which is induced by the anti-PF4/heparin complex and occurs following exposure to heparin. VITT is also very similar to autoimmune HIT (aHIT), which is induced by anti-PF4 but none of these patients had been pre-exposed to heparin before disease onset. Anti-PF4 autoantibodies have also been detected in several autoimmune diseases (e.g., SLE, systemic sclerosis, and RA) [63–65].

PF4 is one of the most abundant proteins in platelet granules and rapidly transported to the surface upon platelet activation. PF4 is present at $>1 \mu\text{g/mL}$ concentrations in plasma. The activation of platelet integrin $\alpha\text{IIb}\beta3$ is a key event that leads to $\alpha\text{IIb}\beta3$ binding to fibrinogen and platelet aggregation. Current models of thrombotic thrombocytopenia (TT) do not include the activation of $\alpha\text{IIb}\beta3$. Chemokines CX3CL1 and CXCL12 are ligands for several integrins and activate integrins in an allosteric mechanism by binding to the allosteric site (site 2) of these integrins, which is distinct from the classical ligand-binding site (site 1). We suspected that PF4 binds to integrin $\alpha\text{IIb}\beta3$ and allosterically activates it. We showed that PF4 binds to soluble integrin $\alpha\text{IIb}\beta3$ in cell-free conditions but did not activate this integrin at physiological PF4 concentrations ($<1 \mu\text{g/mL}$). Notably, an anti-PF4 (RTO)/PF4 complex potently activated soluble $\alpha\text{IIb}\beta3$ in a heparin-independent manner [50]. We propose that anti-PF4 changed the conformation of PF4 and strongly activates $\alpha\text{IIb}\beta3$ by binding to site 2 and results in the strong aggregation of platelets. Since RTO does not require heparin, the PF4/anti-PF4-induced $\alpha\text{IIb}\beta3$ activation may represent aHIT or VITT but not HIT. Our studies connect anti-PF4, PF4, the activation of $\alpha\text{IIb}\beta3$, and subsequent platelet aggregation. We also showed that PF4/anti-PF4 potently activated

vascular integrin $\alpha v\beta 3$, which may play a critical role in autoimmune diseases. We have developed a PF4 mutant that does not induce $\alpha IIb\beta 3$ and $\alpha v\beta 3$ activation by mutating the site 2 binding site in PF4 (predicted by docking simulation). The PF4 mutant acted as an antagonist of the anti-PF4/PF4-induced activation of integrins in ELISA-type activation assays, indicating that it has potential as a therapeutic [50].

16. Conclusions

We identified many integrin ligands through the virtual screening of a protein data bank with the integrin headpiece as a target. Our studies showed that integrins are co-receptors for several growth factors that have different structures and bind to different receptors. Also, we showed that the direct binding to these growth factors to integrins to the classical ligand-binding site (site 1) is required for their signaling functions through the integrin–growth factor–growth factor receptor ternary complex on the cell surface. The growth factor mutants defective in integrin binding are defective in signaling and ternary complex formation, although the mutants still bind to growth factor receptors, indicating that growth factor binding to their cognate receptor is not sufficient for signaling functions. Furthermore, the growth factor mutants defective in integrin binding act as antagonists for signaling functions and suppressed signaling via wild type growth factors (dominant-negative effect). Integrins have an allosteric binding site (site 2), which is distinct from site 1, and many growth factors or pro-inflammatory factors bind to site 2 and activate integrins (opening of site 1) (Figure 6). An inflammatory mediator (25HC) is shown to bind to site 2, activates integrins and induce inflammatory signals, indicating that site 2 is involved in inflammatory signals. Notably, site 2-derived peptides bind to many growth factors/cytokines and blocked allosteric activation, indicating that site 2 peptides have therapeutic potential. The virtual screening of a protein data bank identified an unexpected integrin ligand P-selectin lectin domain. P-selectin binding to integrins and resulting P-selectin signaling and cell–cell interactions are expected to play a role in inflammation and cancer metastasis in addition to P-selectin–PSGL-1 interaction. The inhibitory chemokine PF4 (CXCL4) binds to site 2 but does not activate integrins, indicating that PF4 is a potential site 2 antagonist. Surprisingly, an anti-PF4 antibody changes the phenotype of PF4 from inhibitory to inflammatory. This may be related to the pathogenesis of autoimmune thrombosis or inflammatory diseases, and autoantibodies against PF4 have been detected to these diseases.

Biological and pathological roles of the allosteric activation of integrins. We discovered that the direct binding of growth factors/cytokines to integrins (site 1) and subsequent integrin–cytokine–cognate receptor ternary complex formation is critical for cytokine signaling. Integrins in normal conditions may not be activated in our body fluid with high Ca^{2+} (1 mM). We propose that allosteric activation may enhance cytokine signaling by facilitating ternary cytokine binding to integrins in pathological situations in which levels of inflammatory cytokines in body fluid are increased (e.g., cytokine storm). The activation of $\alpha IIb\beta 3$ via allosteric activation is expected to trigger platelet aggregation. We discovered that the platelet integrin $\alpha IIb\beta 3$ is allosterically activated through several inflammatory proteins (chemokines, CD40L, and CD62P), which are stored in platelet granules and transported to the surface upon platelet activation. Therefore, the allosteric activation of integrins by inflammatory proteins is a potential therapeutic target.




Figure 6. Ligand binding to site 1 and site 2 of $\alpha_v\beta_3$ and $\alpha_{IIb}\beta_3$. Docking simulation predicts that several growth factors/cytokines bind to the classical ligand (RGD) binding site (site 1) and the allosteric site (site 2) in the integrin headpiece. Site 2 is distinct from site 1 and is on the opposite side of site 1. Integrins are not activated in normal conditions. From analogy to allosteric enzymes, site 1 is not open but site 2 is open. It is expected that ligand binding to site 2 of inactive integrins will result in the opening of site 1 (allosteric activation). It appears that this process does not require canonical inside-out signaling (since these ligands activate soluble integrin ectodomain in cell-free conditions) and does not accompany global conformational changes. We propose that allosteric activation is distinct from integrin activation by well-established inside-out signaling. This model can be applied to $\alpha_{IIb}\beta_3$ as well. Notably, most of the allosteric activators that bind to site 2 (e.g., CD40L, CCL5, CXCL12, PF4, and P-selectin) are stored in platelet granules and are rapidly transported to the surface upon platelet activation. Allosteric activation may thus be involved in the activation of $\alpha_{IIb}\beta_3$ and may trigger platelet aggregation.

Author Contributions: Conceptualization, Y.T. and M.F., Writing, Y.T., Data curation, M.F. and Y.K.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Department of Dermatology.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hynes, R.O. Integrins: Bidirectional, allosteric signaling machines. *Cell* **2002**, *110*, 673–687. [[CrossRef](#)] [[PubMed](#)]
2. Takada, Y.; Ye, X.; Simon, S. The integrins. *Genome Biol.* **2007**, *8*, 215. [[CrossRef](#)] [[PubMed](#)]

3. Mori, S.; Wu, C.-Y.; Yamaji, S.; Saegusa, J.; Shi, B.; Ma, Z.; Kuwabara, Y.; Lam, K.S.; Isseroff, R.R.; Takada, Y.K.; et al. Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. *J. Biol. Chem.* **2008**, *283*, 18066–18075. [[CrossRef](#)] [[PubMed](#)]
4. Saegusa, J.; Yamaji, S.; Ieguchi, K.; Wu, C.-Y.; Lam, K.S.; Liu, F.-T.; Takada, Y.K.; Takada, Y. The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling. *J. Biol. Chem.* **2009**, *284*, 24106–24114. [[CrossRef](#)] [[PubMed](#)]
5. Mori, S.; Hatori, N.; Kawaguchi, N.; Hamada, Y.; Shih, T.-C.; Wu, C.-Y.; Lam, K.S.; Matsuura, N.; Yamamoto, H.; Takada, Y.K.; et al. The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. *Biosci. Rep.* **2017**, *37*, BSR20170173. [[CrossRef](#)]
6. Takada, Y.K.; Yu, J.; Shimoda, M.; Takada, Y. Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling. *J. Immunol.* **2019**, *203*, 1383–1391. [[CrossRef](#)]
7. Ieguchi, K.; Fujita, M.; Ma, Z.; Davari, P.; Taniguchi, Y.; Sekiguchi, K.; Wang, B.; Takada, Y.K.; Takada, Y. Direct Binding of the EGF-like Domain of Neuregulin-1 to Integrins ($\alpha\beta3$ and $\alpha6\beta4$) Is Involved in Neuregulin-1/ErbB Signaling. *J. Biol. Chem.* **2010**, *285*, 31388–31398. [[CrossRef](#)]
8. Xiong, J.P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D.L.; Joachimiak, A.; Goodman, S.L.; Arnaout, M.A. Crystal structure of the extracellular segment of integrin alpha Vbeta3. *Science* **2001**, *294*, 339–345. [[CrossRef](#)]
9. Xiong, J.P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S.L.; Arnaout, M.A. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. *Science* **2002**, *296*, 151–155. [[CrossRef](#)]
10. Fujita, M.; Ieguchi, K.; Cedano-Prieto, D.M.; Fong, A.; Wilkerson, C.; Chen, J.Q.; Wu, M.; Lo, S.-H.; Cheung, A.T.W.; Wilson, M.D.; et al. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R. *J. Biol. Chem.* **2013**, *288*, 19593–19603. [[CrossRef](#)]
11. Mori, S.; Tran, V.; Nishikawa, K.; Kaneda, T.; Hamada, Y.; Kawaguchi, N.; Fujita, M.; Takada, Y.K.; Matsuura, N.; Zhao, M.; et al. A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. *PLoS ONE* **2013**, *8*, e57927. [[CrossRef](#)] [[PubMed](#)]
12. Prieto, D.M.C.; Cheng, Y.; Chang, C.-C.; Yu, J.; Takada, Y.K.; Takada, Y. Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling. *PLoS ONE* **2017**, *12*, e0184285. [[CrossRef](#)]
13. Fujita, M.; Takada, Y.K.; Takada, Y. Integrins $\alpha\beta3$ and $\alpha4\beta1$ Act as Coreceptors for Fractalkine, and the Integrin-Binding Defective Mutant of Fractalkine Is an Antagonist of CX3CR1. *J. Immunol.* **2012**, *189*, 5809–5819. [[CrossRef](#)] [[PubMed](#)]
14. Alday-Parejo, B.; Stupp, R.; Rügge, C. Are Integrins Still Practicable Targets for Anti-Cancer Therapy? *Cancers* **2019**, *11*, 978. [[CrossRef](#)]
15. Bazan, J.F.; Bacon, K.B.; Hardiman, G.; Wang, W.; Soo, K.; Rossi, D.; Greaves, D.R.; Zlotnik, A.; Schall, T.J. A new class of membrane-bound chemokine with a CX3C motif. *Nature* **1997**, *385*, 640–644. [[CrossRef](#)]
16. Chapman, G.A.; Moores, K.; Harrison, D.; Campbell, C.A.; Stewart, B.R.; Strijbos, P.J. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. *J. Neurosci.* **2000**, *20*, RC87. [[CrossRef](#)]
17. Garton, K.J.; Gough, P.J.; Blobel, C.P.; Murphy, G.; Greaves, D.R.; Dempsey, P.J.; Raines, E.W. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). *J. Biol. Chem.* **2001**, *276*, 37993–38001. [[CrossRef](#)]
18. Hundhausen, C.; Misztela, D.; Berkhout, T.A.; Broadway, N.; Saftig, P.; Reiss, K.; Hartmann, D.; Fahrenholz, F.; Postina, R.; Matthews, V.; et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. *Blood* **2003**, *102*, 1186–1195. [[CrossRef](#)]
19. Imai, T.; Hieshima, K.; Haskell, C.; Baba, M.; Nagira, M.; Nishimura, M.; Kakizaki, M.; Takagi, S.; Nomiyama, H.; Schall, T.J.; et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. *Cell* **1997**, *91*, 521–530. [[CrossRef](#)]
20. Lucas, A.D.; Bursill, C.; Guzik, T.J.; Sadowski, J.; Channon, K.M.; Greaves, D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). *Circulation* **2003**, *108*, 2498–2504. [[CrossRef](#)]
21. Schafer, A.; Schulz, C.; Eigenthaler, M.; Fraccarollo, D.; Kobsar, A.; Gawaz, M.; Ertl, G.; Walter, U.; Bauersachs, J. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. *Blood* **2004**, *103*, 407–412. [[CrossRef](#)] [[PubMed](#)]
22. Fong, A.M.; Robinson, L.A.; Steeber, D.A.; Tedder, T.F.; Yoshie, O.; Imai, T.; Patel, D.D. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. *J. Exp. Med.* **1998**, *188*, 1413–1419. [[CrossRef](#)] [[PubMed](#)]
23. Goda, S.; Imai, T.; Yoshie, O.; Yoneda, O.; Inoue, H.; Nagano, Y.; Okazaki, T.; Imai, H.; Bloom, E.T.; Domae, N.; et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. *J. Immunol.* **2000**, *164*, 4313–4320. [[CrossRef](#)] [[PubMed](#)]
24. Crow, M.K.; Kirou, K.A. Regulation of CD40 ligand expression in systemic lupus erythematosus. *Curr. Opin. Rheumatol.* **2001**, *13*, 361–369. [[CrossRef](#)]

25. Fujita, M.; Takada, Y.K.; Takada, Y. The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site. *PLoS ONE* **2014**, *9*, e96372. [[CrossRef](#)] [[PubMed](#)]
26. Fujita, M.; Zhu, K.; Fujita, C.K.; Zhao, M.; Lam, K.S.; Kurth, M.J.; Takada, Y.K.; Takada, Y. Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins α v β 3, α 4 β 1, and α 5 β 1. *J. Biol. Chem.* **2015**, *290*, 259–271. [[CrossRef](#)]
27. Fujita, M.; Davari, P.; Takada, Y.K.; Takada, Y. Stromal cell-derived factor-1 (CXCL12) activates integrins by direct binding to an allosteric ligand-binding site (site 2) of integrins without CXCR4. *Biochem. J.* **2018**, *475*, 723–732. [[CrossRef](#)]
28. Takada, Y.K.; Shimoda, M.; Maverakis, E.; Felding, B.H.; Cheng, R.H.; Takada, Y. Soluble CD40L activates soluble and cell-surface integrin α v β 3, α 5 β 1, and α 4 β 1 by binding to the allosteric ligand-binding site (site 2). *J. Biol. Chem.* **2021**, *296*, 100399. [[CrossRef](#)]
29. Saegusa, J.; Akakura, N.; Wu, C.-Y.; Hoogland, C.; Ma, Z.; Lam, K.S.; Liu, F.-T.; Takada, Y.K.; Takada, Y. Pro-inflammatory Secretory Phospholipase A2 Type IIA Binds to Integrins α v β 3 and α 4 β 1 and Induces Proliferation of Monocytic Cells in an Integrin-dependent Manner. *J. Biol. Chem.* **2008**, *283*, 26107–26115. [[CrossRef](#)]
30. Pokharel, S.M.; Shil, N.K.; Gc, J.B.; Colburn, Z.T.; Tsai, S.-Y.; Segovia, J.A.; Chang, T.-H.; Bandyopadhyay, S.; Natesan, S.; Jones, J.C.R.; et al. Integrin activation by the lipid molecule 25-hydroxycholesterol induces a proinflammatory response. *Nat. Commun.* **2019**, *10*, 1482. [[CrossRef](#)]
31. Ginsberg, M.H. Integrin activation. *BMB Rep.* **2014**, *47*, 655–659. [[CrossRef](#)] [[PubMed](#)]
32. Shattil, S.J.; Kim, C.; Ginsberg, M.H. The final steps of integrin activation: The end game. *Nat. Rev. Mol. Cell Biol.* **2010**, *11*, 288–300. [[CrossRef](#)] [[PubMed](#)]
33. Han, J.; Lim, C.J.; Watanabe, N.; Soriani, A.; Ratnikov, B.; Calderwood, D.A.; Puzon-McLaughlin, W.; Lafuente, E.M.; Boussiotis, V.A.; Shattil, S.J.; et al. Reconstructing and deconstructing agonist-induced activation of integrin α IIb β 3. *Curr. Biol.* **2006**, *16*, 1796–1806. [[CrossRef](#)]
34. Schürpf, T.; Springer, T.A. Regulation of integrin affinity on cell surfaces. *EMBO J.* **2011**, *30*, 4712–4727. [[CrossRef](#)] [[PubMed](#)]
35. Bunch, T.A. Integrin α IIb β 3 activation in Chinese hamster ovary cells and platelets increases clustering rather than affinity. *J. Biol. Chem.* **2010**, *285*, 1841–1849. [[CrossRef](#)] [[PubMed](#)]
36. Bakogiannis, C.; Sachse, M.; Stamatielopoulos, K.; Stellos, K. Platelet-derived chemokines in inflammation and atherosclerosis. *Cytokine* **2019**, *122*, 154157. [[CrossRef](#)]
37. Bleul, C.C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* **1996**, *382*, 829–833. [[CrossRef](#)]
38. Bleul, C.C.; Fuhlbrigge, R.C.; Casasnovas, J.M.; Aiuti, A.; Springer, T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). *J. Exp. Med.* **1996**, *184*, 1101–1109. [[CrossRef](#)]
39. Balabanian, K.; Lagane, B.; Infantino, S.; Chow, K.Y.C.; Harriague, J.; Moepps, B.; Arenzana-Seisdedos, F.; Thelen, M.; Bachelier, F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J. Biol. Chem.* **2005**, *280*, 35760–35766. [[CrossRef](#)]
40. Burns, J.M.; Summers, B.C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M.E.T.; Sunshine, M.J.; Littman, D.R.; Kuo, C.J.; et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J. Exp. Med.* **2006**, *203*, 2201–2213. [[CrossRef](#)]
41. Busillo, J.M.; Benovic, J.L. Regulation of CXCR4 signaling. *Biochim. Biophys. Acta* **2007**, *1768*, 952–963. [[CrossRef](#)] [[PubMed](#)]
42. Vlahakis, S.R.; Villasis-Keever, A.; Gomez, T.; Vanegas, M.; Vlahakis, N.; Paya, C.V. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. *J. Immunol.* **2002**, *169*, 5546–5554. [[CrossRef](#)] [[PubMed](#)]
43. Grewal, I.S.; Flavell, R.A. CD40 and CD154 in cell-mediated immunity. *Annu. Rev. Immunol.* **1998**, *16*, 111–135. [[CrossRef](#)] [[PubMed](#)]
44. Schonbeck, U.; Libby, P. The CD40/CD154 receptor/ligand dyad. *Cell Mol. Life Sci.* **2001**, *58*, 4–43.
45. Delmas, Y.; Viallard, J.-F.; Solanilla, A.; Villeneuve, J.; Pasquet, J.-M.; Belloc, F.; Dubus, I.; Dachanet-Merville, J.; Merville, P.; Blanco, P.; et al. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. *Kidney Int.* **2005**, *68*, 2068–2078. [[CrossRef](#)]
46. Alaaeddine, N.; Hassan, G.S.; Yacoub, D.; Mourad, W. CD154: An immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. *Clin. Dev. Immunolog.* **2012**, *2012*, 490148. [[CrossRef](#)]
47. Hassan, G.S.; Stagg, J.; Mourad, W. Role of CD154 in cancer pathogenesis and immunotherapy. *Cancer Treat. Rev.* **2015**, *41*, 431–440. [[CrossRef](#)]
48. Hassan, G.S.; Merhi, Y.; Mourad, W. CD40 Ligand: A neo-inflammatory molecule in vascular diseases. *Immunobiology* **2012**, *217*, 521–532. [[CrossRef](#)]
49. André, P.; Prasad, K.S.; Denis, C.V.; He, M.; Papalia, J.M.; Hynes, R.O.; Phillips, D.R.; Wagner, D.D. CD40L stabilizes arterial thrombi by a β 3 integrin-dependent mechanism. *Nat. Med.* **2002**, *8*, 247–252. [[CrossRef](#)]
50. Takada, Y.K.; Wu, C.Y.; Takada, Y. Anti-PF4 (heparin-independent)/PF4 complex induces allosteric activation of integrins α IIb β 3 and α v β 3, a potential mechanism of vaccine-induced thrombotic thrombocytopenia (VITT) and autoimmune diseases. *bioRxiv* **2022**. [[CrossRef](#)]
51. Piirilä, H.; Väliäho, J.; Vihinen, M. Immunodeficiency mutation databases (IDbases). *Hum. Mutat.* **2006**, *27*, 1200–1208. [[CrossRef](#)] [[PubMed](#)]

52. Andre, P.; Nannizzi-Alaimo, L.; Prasad, S.K.; Phillips, D.R. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. *Circulation* **2002**, *106*, 896–899. [[CrossRef](#)] [[PubMed](#)]
53. Fiocchi, C.; Danese, S. Platelet activation and the CD40/CD40 ligand pathway: Mechanisms and implications for human disease. *Crit. Rev. Immunol.* **2005**, *25*, 103–122. [[CrossRef](#)] [[PubMed](#)]
54. Alturaihi, H.; Hassan, G.S.; Al-Zoobi, L.; Salti, S.; Darif, Y.; Yacoub, D.; El Akoum, S.; Oudghiri, M.; Merhi, Y.; Mourad, W. Interaction of CD154 with different receptors and its role in bidirectional signals. *Eur. J. Immunol.* **2015**, *45*, 592–602. [[CrossRef](#)] [[PubMed](#)]
55. Wagner, D.D. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. *Thromb. Haemost.* **1993**, *70*, 105–110. [[CrossRef](#)]
56. Palabrica, T.; Lobb, R.; Furie, B.C.; Aronovitz, M.; Benjamin, C.; Hsu, Y.-M.; Sajer, S.A.; Furie, B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. *Nature* **1992**, *359*, 848–851. [[CrossRef](#)]
57. Mayadas, T.N.; Johnson, R.C.; Rayburn, H.; Hynes, R.O.; Wagner, D.D. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. *Cell* **1993**, *74*, 541–554. [[CrossRef](#)]
58. Vestweber, D.; Blanks, J.E.; Zhang, S.; Song, L.; Wang, Y.; Herwald, H.; Thorlacius, H.; Yamada, Y.; Kobayashi, H.; Iwasa, M.; et al. Mechanisms that regulate the function of the selectins and their ligands. *Physiol. Rev.* **1999**, *79*, 181–213. [[CrossRef](#)]
59. Springer, T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. *Cell* **1994**, *76*, 301–314. [[CrossRef](#)]
60. Ludwig, R.J.; Schon, M.P.; Boehncke, W.H. P-selectin: A common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. *Expert Opin. Ther. Targets* **2007**, *11*, 1103–1117. [[CrossRef](#)]
61. Takada, Y.K.; I Simon, S.; Takada, Y. The C-type lectin domain of CD62P (P-selectin) functions as an integrin ligand. *Life Sci. Alliance* **2023**, *6*, e202201747. [[CrossRef](#)] [[PubMed](#)]
62. Mehta-D'Souza, P.; Klopocki, A.G.; Oganessian, V.; Terzyan, S.; Mather, T.; Li, Z.; Panicker, S.R.; Zhu, C.; McEver, R.P. Glycan Bound to the Selectin Low Affinity State Engages Glu-88 to Stabilize the High Affinity State under Force. *J. Biol. Chem.* **2017**, *292*, 2510–2518. [[CrossRef](#)] [[PubMed](#)]
63. Satoh, T.; Tanaka, Y.; Okazaki, Y.; Kaburaki, J.; Ikeda, Y.; Kuwana, M. Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus. *Rheumatology* **2012**, *51*, 1721–1728. [[CrossRef](#)]
64. Lande, R.; Mennella, A.; Palazzo, R.; Pietraforte, I.; Stefanantoni, K.; Iannace, N.; Butera, A.; Boirivant, M.; Pica, R.; Conrad, C.; et al. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. *Int. J. Mol. Sci.* **2020**, *21*, 5102. [[CrossRef](#)] [[PubMed](#)]
65. Izumi, M.; Sakai, T.; Shirakawa, A.; Kozuru, H.; Jiuchi, Y.; Izumi, Y.; Asahara, T.; Kumagai, K.; Mawatari, M.; Osaki, M.; et al. Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty. *Arthritis. Res. Ther.* **2016**, *18*, 191. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.